Cytovale Builds Momentum as IntelliSep Adoption Grows and Sepsis Standards Tighten

Cytovale continued to sharpen its focus on sepsis diagnostics this week, emphasizing how evolving SEP-1 quality measures and antibiotic stewardship are reshaping emergency department strategies. The company linked multiple Becker’s Healthcare webinars to its positioning, underscoring the risks of overdiagnosis, overtreatment, and misclassification in sepsis care.

Clinical leaders from FMOL Health and Jefferson Health – Lehigh Valley highlighted how early sepsis decision-making can materially impact hospital capacity and reimbursement. One health system cited operational gains comparable to adding an 85-bed hospital by improving early sepsis decisions without new construction.

Cytovale framed its sepsis decision-support offerings as tools that can help health systems balance regulatory compliance with diagnostic precision while supporting value-based purchasing. The messaging suggests growing demand for technologies that improve risk stratification, throughput, and quality metrics in high-acuity settings.

The company also reported expanded deployment of its IntelliSep sepsis risk assessment tool within the Froedtert and Medical College of Wisconsin Health Network. IntelliSep is now in use at Froedtert Health Menomonee Falls Hospital, a community emergency department treating more than 24,000 patients per year.

Cytovale highlighted real-world data from a propensity-matched study of over 6,000 emergency patients with suspected infection at Froedtert Hospital. IntelliSep use in that setting was associated with a 42% reduction in mortality and roughly two fewer hospital days, bolstering the product’s clinical and economic value proposition.

In parallel, the company aligned its communications with National Hospital Week and Maternal Sepsis Week, spotlighting pressures from rising patient volumes, staffing constraints, and complex populations. It pointed to maternal sepsis, with an estimated 261,000 deaths annually worldwide, as an area where early host-response diagnostics may address subtle and easily missed symptoms.

Across its communications, Cytovale reiterated the limitations of current sepsis diagnostic pathways that often force clinicians into aggressive treatment without precise tools. By promoting immune-response–based diagnostics and workflow-aligned decision support, the company is positioning itself as a partner in improving acute-care performance and patient safety.

Taken together, the week’s developments suggest growing clinical traction for IntelliSep and a tighter alignment of Cytovale’s strategy with evolving hospital standards and value-based incentives. These trends could support broader adoption of the company’s sepsis solutions and reinforce its long-term position in the acute-care diagnostics market.